Analysis of CMTM6 Expression in Patients With Acute Myeloid Leukemia
NCT ID: NCT05988047
Last Updated: 2024-05-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
150 participants
OBSERVATIONAL
2020-05-01
2024-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Relationship Between Serum N/OFQ and Acute Myeloid Cell Leukemia
NCT06469047
Molecular Diagnostic Platform for AML
NCT04446741
Expression Pattern and Possible Clinical Significance of CD81 In Myeloid Leukemia
NCT07146542
Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia
NCT05893836
Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms
NCT01650467
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with AML
Peripheral blood will be taken at the timepoint of primary diagnosis and analyzed for CMTM6 expression and T cell activation
No interventions assigned to this group
Healthy controls
Peripheral blood will be taken analyzed for CMTM6 expression and T cell activation
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* primary diagnosis of acute myeloid leukemia
* diagnosis results available
* written informed consent
* ability to understand the nature of the study and the study related procedures and to comply with them
Exclusion Criteria
* lack of informed consent
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Freiburg
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Robert Zeiser
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Center- University of Freiburg
Freiburg im Breisgau, CA, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CMTM6_AML
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.